Checkpoint Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Checkpoint Therapeutics

10/08/2024 24:58

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 12 (estimated) for the period ending June 30 2024
    * The Waltham Massachusetts-based  company is expected to
report a
50.0% decrease in revenue to $15.5 thousand from $31 thousand a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Checkpoint Therapeutics
Inc is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $27.00​, above​ its last closing price
of $2.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.29       -0.27      -0.33     Missed  -20.7
 Dec. 31 2024              -0.54      -1.10     Missed  -102.5
 Jan. 1 0001   -0.75       -0.76      -0.29     Beat    61.8​
 Jun. 30 2023  -0.77       -0.78      -1.05     Missed  -34.6
 ​​Mar.        -1.09       -1.07      -0.89     Beat    16.6
 31 2023                                                
 Dec. 31 2022  -1.30       -1.31      -2.29     Missed  -75.3​
 Sep. 30 2022  -1.47       -1.47      -1.20     Beat    18.2
 Jun. 30 2022  -1.78       -1.72      -1.60     Beat    7.2
 This summary was machine generated August 9 at 23:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)